Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $3.50 and keeps an Equal Weight rating on the shares. Q4 results were modestly ahead of expectations, but based on Q1 guidance missing and deferring FY26 guidance, the firm says some incremental pressure on FY26 arose since Q3 and/or January preliminary results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $3 from $4 at Cantor Fitzgerald
- Health Catalyst price target lowered to $2 from $3.75 at Stifel
- Health Catalyst price target lowered to $2 from $5 at Canaccord
- Health Catalyst price target lowered to $1.75 from $2.75 at Citi
- Health Catalyst reports Q4 adjusted EPS 8c, consensus 10c